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INTRODUCTION
It is widely accepted that combination chemotherapy has a be nefi t to increase effi cacies at lower dose and less side-effects compared to single chemotherapy with high dose. Previous researches have shown that combination chemotherapies are even effective for some cancer cell lines that are resistant to anticancer drugs. Combination chemotherapy has demonstrated high survival benefi ts especially in treating prostate cancer and particularly in the cases of hormone refractory and metastatic disease state (Beltran et al., 2011) . Recently, it has been reported that induction of apoptosis through administration of TRAIL can be effective in treating prostate cancer cells both in-vivo and in-vitro (Simons et al., 1999; Shankar et al., 2005) . TRAIL is a member of the TNF (tumor necrosis factor) super-family of cytokines that induces apoptosis in a variety of cancer cell lines via death receptors (DR4, DR5) on the cell surface (Zhang and Fang, 2005) . TRAIL has attracted significant attention due to its ability to selectively induce apoptosis in human tumor cells, while having minimal toxicity effects to normal cells (Sheikh and Fornace, 2000; Kelley and Ashkenazi, 2004; Bouralexis et al., 2005) . Despite of the attractive advantage of TRAIL as anticancer drug, some cancer cell lines are inherently resistant to TRAIL-mediated apoptosis. The toxicity could increase in normal cells when the concentration of TRAIL is escalated to treat the resistant cancer cells. To enhance cancer cell sensitivity to the TRAIL, therapeutic strategies involving DNA-damaging genotoxins (Ohtsuka et al., 2003) , radiotherapy (Shankar et al., 2004) , and peptides (Barua et al., 2010) have been investigated. Diverse agents including anticancer drugs and many natural compounds were treated with TRAIL as a sensitizer to enhance cancer cell sensitivity. Among them, combination treatment of TRAIL with naturally occurring phytochemical compounds have been known as the effective method due to its inexpensiveness and nontoxic property to normal cells (Shankar et al., 2007; Siddiqui et al., 2008; Amin et al., 2009 powder, is one of the natural components used to enhance the cancer cell sensitivity to TRAIL for treating cancer cells at lower concentrations, thereby minimizing the damage to normal cells. In India and Asia, turmeric is used for treating many health conditions and is reported to have anti-infl ammatory, antioxidant, and perhaps even anticancer properties (Aggarwal et al., 2003; Wilken et al., 2011) . In order to identify an appropriate sensitizer and fi nd effective drug combinations that induce apoptosis of cancer cell lines resistant to anticancer drug, a large number of experimental platforms to screen variety of concentrations/combinations are required. Therefore, a high throughput drug screening (HTDS) system is the perfect candidate. The HTDS has become the most important and integrated part in drug discovery in most pharmaceutical and many biotechnology industries worldwide, and is now entrenched in the drug discovery processes (Hung et al., 2005a; Hung et al., 2005b) . Compared to microfl uidic system based HTDS systems, the conventional cell based HTDS systems require cumbersome processes such as cell loading and drug treatment using expensive robotic equipment. To overcome this limitation, many research groups have applied microfl uidic technologies to develop HTDS systems. Although previously introduced microfl uidic based HTDS were very successful, they required multiple tubing connections and syringe pumps for operation that results in large dead volume in tubing and connection parts (Wang et al., 2007; Kim et al., 2010a; Kim et al., 2010b) . Here, we report a fully automated microfl uidic system based HTDS with the integrated micropump system which does not require any external syringe pump or tubing connections for combinatorial screening of drugs. The integrated micropump system is composed of array of valves operating individually. Two sets of micropumps, one for anticancer drug and the other for sensitizer, operate automatically and independent from each other. Anticancer drugs and sensitizer are introduced into each of gradient mixer and generate 8 different concentrations for each and delivered into cell culture chambers, resulting in 64 different combinations in 64 chambers. Therefore, this tubingless microfl uidic system based HTDS to perform effi cient and facile combinational chemotherapy could be used as the methodological technique in pharmaceutical and many biotechnology industries. We demonstrate that this fully automated and integrated platform could be optimized for the combinational condition of curcumin concentration as sensitizer to TRAIL against prostate cancer PC3 cell line.
MATERIALS AND METHODS

Cells and materials
Human prostate cancer PC3 cells (Korean Cell line Bank, Seoul, Korea) were cultured and propagated in RPMI cell culture medium with 10% fetal bovine serum (WelGENE, Seoul, Korea) and 100 U/ml penicillin and 100 μg/μl streptomycin at 37 o C under 5% CO 2 and 95% atmospheric air in 95% humidity incubator under 85% cell confl uence. The use of Cell from passage 4 is described as follows. Curcumin (C1386) and TRAIL (Recombinant human, 375-TEC) were purchased from Sigma-Aldrich (St. Louis, MO, USA) and R&D systems (Minneapolis, MN, USA), and stored at a stock concentration of 40 mM and 1 μg/ml in starvation media respectively. The Live/Dead assay kit (L-3224) was purchased from Invitrogen (Carlsbad, CA, USA).
Microfl uidic device design and fabrication
Soft lithography (the previously reported protocol [Whitesides et al., 2001; Kim et al., 2010a; Kim et al., 2010b; Kim et al., 2012a; Kim et al., 2012b] ) was used for t fabrication of the microfl uidic device in poly dimethyl siloxane (PDMS (Sylgard 184, Dow Corning)). This device consists of two layers -one for the fl uidic layer that contains the diffusive mixer to generate a concentration gradient and microchambers to culture the cells and the other for the pneumatic layer that has 10 channels to control the microvalves on the fl uidic layer independently (Fig. 1) . The fl uidic channel has 8×8 chamber array and two concentration gradient generators with two micropumps for the sequential drug treatment. Each micropump has a reservoir holding 100 μl volume to introduce the reagent into the microchannels. Pneumatic layer is composed of three parts; two valve groups to operate the micropump for generating the fl ow and maintaining the cell culture, gradient valves to isolate the diffusive mixer from injected cells through two outlets during seeding process, and directional valves to de- www.biomolther.org termine the fl ow direction of the generated gradient between two orthogonal direction in culture chamber arrays. Using the soft-lithography technology, a channel structures on silicon wafer were pattered using SU-8 2050 (Microchem, Newton, MA, USA) photo resistant as a master mold. PDMS was mixed with a 10:1 ratio between the base and curing agent, and after that the precursor PDMS mixture was poured on the master mold in a petri dish to obtain pneumatic layer with 4 mm thickness. The master mold for fl uidic layer was spin-coated at 800 rpm for 30 seconds after pouring the PDMS precursor to fabricate the thin membrane with uniform thickness of 150 μm. In order to make a fl at surface, these PDMS coated master molds were placed on a hotplate without heating for 10 minutes prior to baking at 70 o C for 2 hrs. After baking, patterned PDMS bas-relief layer for pneumatic channel and membrane layer for fl uidic channel were peeled from the master molds. PDMS bas-relief layer was punched with 19 gauge sharpened fl at top needle to connect the pneumatic controlling tygon tubing. Two PDMS layers were then assembled after exposing to oxygen plasma aligned between the pneuma tic channel and the fl uidic channel. Methanol was used as a lubricant to freely move around layers during aligning, and then was baked at 70 o C for 8 hrs. Assembled PDMS device was punched to create the reservoirs prior to bonding it with a glass slide with oxygen plasma treatment. Before attaching the PDMS device to the slide glass, all pneumatic valves were keep opened by applying the negative pressure to prevent the surface of mi crovalves from permanent bonding to the glass slide. This process provides two layer PDMS structure with integrated microvalves fabricated without additional complex and time-consuming processes. The peristaltic micropump was composed of two microvalves and one actuator powered by pneumatic pressure was controlled by LabVIEW program. The detailed operating scheme of the peristaltic pump system is described in previously published research paper (Unger et al., 2000; Li et al., 2005; Lai and Folch, 2011; Graf and Bowser, 2013) . The fl ow rate was controlled with a diameter of actuator and also the frequency of operating cycles of micropump pneumatic components. Since to assemble the micropump on microfl uidic chip, any complex tubing and bulky syringe pump were not required to support the fl ow, it is so easy to handle the system for moving between microscope and cell culture incubator compared to previous systems (Kim et al., 2010a; Kim et al., 2010b) . In addition, using the peristaltic pump provides much more stable fl uidic fl ow in generating gradient with the diffusive mixer compared to syringe pumps where uneven back fl ow possibly causes the fl ow irregularity such as droplet generation. (Garstecki et al., 2006) The commercial pneumatic controller (NV-PNEUMARO 4, NavibioTech [Cheonan, Korea]) having 10 independent controlled pneumatic ports to operate the system automatically were used and the system was synchronized with LabVIEW software to automatically operate the pneumatic components in the microfl uidic device during the entire experiment.
Cell experiment in 96-well plates
Controlled combination chemotherapy experiments were performed in a 96 well plate. PC3 cells were seeded with density of 8000 cells/ml (1600 cells per well). After culturing the cells for 24 hrs at 5% CO 2 incubator, previous growth medium was changed to fetal bovine serum free medium and incubated for 5 hrs. PC3 cells were incubated with 0 to 40 μM curcumin contained medium for 24 hrs followed by 20 ng/ml TRAIL treatment for 24 hrs.
Generation of two drug concentrations in the microdevice
The microfl uidic device has orthogonal cell culture chambers of 8×8 arrays. Each directional chamber arrays were connected with a concentration gradient generator containing reservoir. 8 different concentrations of drugs were generated by the fl ow by the micropump. 8 different concentrations of drug were introduced into cell culture chambers by opening the gradient valve and the directional valves with horizontal direction. The cell culture chamber arrays that are orthogonally positioned were exposed to 8 different concentrations with the same method after pretreated with sensitizer for 24 hrs. Therefore, 64 cell culture chambers were exposed 64 different combinations of sensitizer and drug. The valve and the pump actuation were automatically controlled by LabVIEW interface, enabling fully automated multi-day sequential cancer drug assay. The gradient generators were profi led through FITC by changing the parameter of micropump on LabVIEW system. (Fig. 3) The intensity of fl uorescent shows the linear gradient profi le increasing the FITC concentration in Fig. 3C .
Cell culture and drug treatment
The microfl uidic device was sterilized under UV for 20 min. Slide glass surface of fl uidic channel was coated with 50 μg/ ml collagen I and kept at 4 o C for 12 hrs followed by removal of excessive collagen I with RPMI 1640 medium. PC3 cells were seeded into the cell culture chambers by controlling the micro valves using syringe pump at 12 μl/min fl ow rate, the valves around the cell culture chamber array were closed to prevent the invasion of cells into unexpected area such as diffusive mixer. After seeding, all valves were closed to help attach the cells on collagen I coated surface in cell culture chambers. The seeded cells were then incubated in 37ºC, 5% CO 2 incubator for 18 hrs with refreshing medium every 4 hrs. After cell loading, each reservoir of a concentration gradient generator was fi lled with fresh medium and curcumin as the sensitizer respectively with closing all valves. For the drug treatment, all micro pumps for cell culture array were opened, introducing 8 different concentrations (from 0 μM to 40 μM) of curcumin. This treatment process was repeated every 4 hrs for refreshment. Also, TRAIL as anticancer drug was exposed into cell culture chambers through the other concentration gradient generator by same way after fi nishing the treatment of sensitizer.
Cell apoptosis assay
Post drug exposed cells were washed with 1×PBS (phosphate buffered saline) to remove dead cells and then Live/ Dead kit was introduced into cell culture chambers through left or right micro pump to stain the cells. Calcein AM indicates live cells with green fl uorescent and ethidium homodimer indicates dead cells with red fl uorescent. After introducing Live/ Dead kit, cells were kept in the dark for 30 min and washed with 1×PBS to rinse the cells. Stained cells were visualized and observed under a fl uorescence microscope (AxioObserver D1, Carl Zeiss). In 96 well plate experiments, MTT assay was performed after combination drug treatment to verify cell viability. This result was compared with experiment in microfl uidic device.
RESULTS
Characterization of concentration gradients in the device
The microfl uidic channel has 8×8 chamber array and two con centration gradient generators with two micropumps for the sequential drug treatment (Fig. 1) . Different concentrations of curcumin and TRAIL were generated in the array using two diffusive mixers in conjunction with micropumps in the single microfl uidic system. Fig. 2 . demonstrates the combination array of two color dyes of 8 different concentration gradients generated in the microfl uidic device sequentially. The single concentration gradient can be generated in a standard diffusive mixer where the linear concentration gradient from the minimum to the maximum concentration is represented as different colors (from yellow to blue dye solutions shown in Fig. 2A ). In this system, the other concentration gradient by different solution in perpendicular to fl ow of sensitizer is re presented as the different colors of dye solution (yellow to red representing yellow as minimum concentration). During www.biomolther.org gradient generation, the microvalve array separates the each neighbor concentration solution with unique concentration at one row and column respectively. Fig. 2C demonstrates operation of microvalve with closing and opening. Quantitation of 64 combinations generated using 0-10 mM each of FITC and Rhodamine B was performed (not shown). A concentration gradient of solution was established in the diffusive mixer which whole solution in the chip was fl owed by micropump from the reservoir to the cell culture chamber and the solution was trapped in the cell culture chamber array for 4 hrs by closing the valves before refreshing the concentration gradient. This operation mimics the replenishment of media in the cell culture chamber with fresh media. Most microfl uidic systems (Neils et al., 2004; Lee et al., 2006 ) using a diffusive mixer require continuous perfusion of solutions to maintain concentration gradients. However, continuous perfusion has several li mitations. First, a large amount of drug is consumed for each experiment. Second, cells cultured in the microfl uidic channel are continuously exposed to signifi cant shear stress. On the other hand, our system does not require continuous perfusion during the process that cells are cultured and also is always exposed to drug except for the period when generating the concentration gradient (30 seconds). Therefore, this system would be advantageous for culturing cells that are sensitive to shear stress and has benefi ts in using expensive or less amount of drug for high throughput screening.
Culture of PC3 cells in the microfl uidic device
In this study, the prostate cancer cell line PC3 was used for combinatorial drug treatment with the developed system. PC3 cells were introduced and captured into the cell culture chamber array and maintained for 24 hrs with media being refreshed every 3.5 hrs in humidity incubator with 5% CO 2 at 37ºC to adapt at the microfl uidic environment prior to drug treatment. PC3 cells were cultured in the device without any adverse effect from the microfl uidic environment for 7 days (not shown). Fig. 2D shows that a representative PC3 cells grown in culture chamber array for 24 hrs.
Drug treatment with TRAIL and curcumin as sensitizer
Microfl uidic cell array system was investigated to understand e the effect of the combinatorial treatment of TRAIL and curcumin as a sensitizer in the viability of PC3 human prostate cancer cell line. PC3 cells were cultured in microfl uidic cell cul ture array and treated sequentially with different concentrations combination of TRAIL and curcumin. First, PC3 cells in cell culture chamber were treated with different concentrations of curcumin. Based on the lethal concentration 50 (LC 50 ) values for PC3 cells in prior reports, the concentration range of curcumin was decided (Adam et al., 2012; Heger et al., 2014) . The concentration range was less than that of the LC 50 value to investigate the potential sensitizing activity of curcumin as sensitizer to TRAIL. The concentration gradient of curcumin was generated by the diffusive mixer with two streams of 0 and 40 μM curcumin. After 24 hrs exposure to these concentrations of curcumin, a gradient of 0-10 ng/ml TRAIL was generated and treated for 24 hrs. The cell viability was determined with counting the live cells after Live/Dead staining. Fig. 4A shows representative fl uorescent micrographs of cell chamber array in a single experiment. The data in the insets (Fig. 4B) show that cells in cell culture chamber without curcumin and TRAIL have proliferated and are confl uent (top left as control). Treatment with 40 μM of curcumin (top right) or 10 ng/ ml of TRAIL (bottom left) alone shows less viability, whereas both exposure to 40 μM curcumin and 20 ng/ml TRAIL with sequential treatment shows very few live cells. The fraction of live cells in each cell culture chamber was determined. Fig.  5A shows that single treatment of TRAIL without curcumin as sensitizer leads to a dose-dependent decrease with ~30% in cell viability compared to highest concentration (20 ng/ml). Curcumin also induces loss cell viability in PC3 as seen from a dose-dependent decrease compared with the absence of TRAIL. The effect of curcumin as sensitizer shows from 23 μM concentration of curcumin exposed on PC3 cell with TRAIL. The cell viability decreases from 50% in the curcumin alone to 20% with an increase in the concentration of TRAIL. This ex tent of decrease at 23 μM concentration of curcumin is signifi cant compared with smaller amount at lower and higher concentrations of curcumin, as could be expected. In the lower concentration, the concentration of curcumin is not enough to fully sensitize PC3 cells to TRAIL-mediated cell death. On the other hand, curcumin by itself decreases cell viability in the higher concentration. The objective of combinational chemotherapy is to fi nd out the optimized combination conditions among the concentrations of sensitizer with the lowest concentration of drug to minimize the side effect by the drug. In this curcumin as sensitizer on PC3 cells, the combination of 23 μM curcumin with 14 ng/ml of TRAIL is suffi cient to reduce cell viability by 90%. Our results imply that the optimal concentration of curcumin for sensitizing PC3 cells at lower dose TRAIL treatment is about ~23 μM and these results obtained with the microfl uidic device were compared to those in 96-well plate (Fig. 5B) . The combination treatment in the device results in rather smaller increase in PC3 cell viability than those in well plate. The above difference was estimated with comparing the LC 50 values obtained for combination treatment in microfl uidic device and 96-well plate ( Table 1 ) which means that using microfl uidic system for cell based combination therapy is more effective than well plate. There are several possible differ- Fig. 5 . PC3 cell viability after sequential exposure to curcumin and TRAIL. PC3 cells were initially exposed to (A) in microfl uidic system with eight concentrations (0.0, 5,71, 11.4, 17.1, 22.9, 28.6, 34.3, and 40 .0 mM) of curcumin for 24 hrs, followed by exposure to eight concentrations (0.0, 2. 86, 5.71, 8.57, 11.4, 14.3, 17 .1, and 20.0 ng/ml) of TRAIL for 24 hrs. (B) in 96-well plate. Data is taken after averaging three independent experiments. ences in drug effi cacy between two formats. First, both the periodic media replenishment with fresh reagent (sensitizer and anticancer drug) and the removal of waste products every 4 hrs were used for the microfl uidic device. It is not possible to do in well plate with replenishment every 4 hrs during a couple of days with manual operation. The consumption of reagent using well plate (especially expensive anticancer drug) is also much bigger than that in microfl uidic system. The volume of a cell culture chamber in the microfl uidic device is only 48 nl, so total volume inside is under 4 μl. In this single replenishment for 8×8 combination treatment in microfl uidic system, the total reagent had been spent only 10 μl including media with highest concentration.
DISCUSSION
In this paper, we have developed a fully automated and programmable high throughput drug screening system based on microfl uidic chip to perform combinational chemotherapy with 64 pair-wise concentration combinations between sensitizer and drug (Fig. 2) . The consumption of reagent was minimized under 100 μl for entire experiment by including micropump on microfl uidic system. Our results have benefi ts for some usual biological experiments having limitation of reagent which always involving a small amount or expensive purifi ed natural component or anticancer drug. In addition, the cost for this cell array microfl uidic device with massive production is not expensive comparing to that of conventional multi-well plate. The microfl uidic system has been characterized using a natural curcumin component as a sensitizer for TRAIL-induced cell death against prostate cancer PC3 cells. Previous researches have shown that sensitization of prostate cancer cells by curcumin inhibits the activation of NF-κB in cells to sensitize prostate cancer PC3 cells to TRAIL (Deeb et al., 2004; Deeb et al., 2006; Deeb et al., 2007) . We have also demonstrated that the optimal concentration of curcumin for sensitizing prostate cancer PC3 cells at lower dose TRAIL treatment is about ~23 μM (Fig. 5) . Other researches have shown that characterizing the in vitro LC 50 concentration of curcumin alone is against diverse cancer cell types, because of pharmacologically safety of curcumin comparing to the toxicity of synthetic reagents (Heger et al., 2014) . This system can be useful to verify the optimization of curcumin concentration against the other cancer cells with low dose TRAIL treatment. Our results in microfl uidics system are more sensitive than in well plate because of frequent replenishment of fresh media and drug solution (Table 1) . These facts have an advantage in deciding the range of drug dosage for animal experiments. The another aspect of benefi ts is that this method does not require large consumption of labor and time for combinational drug screening among multi-drug because of fully automated system. It could help minimize the individual deviation by experimenter with standardization. This HTDS should be useful for screening experiment from cloud to specifi c ranges. This system can be extended to identifying combinatorial drug treatments for a variety of in-vitro disease models. Finally, the ability to carry out sequential treatment also facilitates exploration of diverse dosing studies for new drug development.
